Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial

tAnGo trial collaborators, Helena M. Earl*, Louise Hiller, Helen C. Howard, Janet A. Dunn, Jennie Young, Sarah J. Bowden, Michelle McDermaid, Anna K. Waterhouse, Gregory Wilson, Rajiv Agrawal, Susan O'Reilly, Angela Bowman, Diana M. Ritchie, Andrew Goodman, Tamas Hickish, Karen McAdam, David Cameron, David Dodwell, Daniel ReaCarlos Caldas, Elena Provenzano, Jean E. Abraham, Peter Canney, John P. Crown, M. John Kennedy, Robert Coleman, Robert C. Leonard, James A. Carmichael, Andrew M. Wardley, Christopher J. Poole

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)
138 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences